OncoMatch/Clinical Trials/NCT06517017
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Is NCT06517017 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Isatuximab for multiple myeloma.
Treatment: Isatuximab — Historically, the frailest patients with multiple myeloma are under-represented in clinical trials, and have very high rates of treatment discontinuation, and early treatment mortality. The investigators hypothesize that a go-slow gentle approach to starting treatment in such patients, starting with just Isatuximab and dexamethasone with a gentle introduction to lenalidomide third cycle onwards, may improve treatment adherence and quality of life. The goal of this clinical trial is to learn if a go-slow approach to treating MM in ultra-frail patients may improve the ability to adhere to treatment and improve quality of life.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute at the University of Utah · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify